Direct-Acting Oral Anticoagulant Choice for Stroke Prevention in Obese Patients With Atrial Fibrillation-Reference-Cited by-同舟云学术

Direct-Acting Oral Anticoagulant Choice for Stroke Prevention in Obese Patients With Atrial Fibrillation

Published:2021-09 Issue:9 Volume:37 Page:1489-1492
ISSN:0828-282X
Container-title:Canadian Journal of Cardiology
language:en
Short-container-title:Canadian Journal of Cardiology

Author:

Brar Tanveer,Chua Doson

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference5 articles.

1. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)

2. The “obesity paradox” in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial;Sandhu;Eur Heart J,2016

3. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial;Boriani;Eur Heart J,2019

4. The use of dabigatran according to body mass index: the RE-LY experience. Poster presented at: European Society of Cardiology Congress 2014;Ezekowitz;Eur Heart J,2014

5. Nonvitamin K Antagonist oral anticoagulant for atrial fibrillation in obese patients;SY;Am J Cardiol,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factor Xa inhibitors versus warfarin in severely obese patients with venous thromboembolism or atrial fibrillation;American Journal of Pharmacotherapy and Pharmaceutical Sciences;2024-02-29

2. Direct oral anticoagulants and the risk of adverse clinical outcomes among patients with different body weight categories: a large hospital-based study;European Journal of Clinical Pharmacology;2023-11-18

3. A Real-World Comparison of Apixaban and Rivaroxaban in Obese and Morbidly Obese Patients With Nonvalvular Atrial Fibrillation;Journal of Pharmacy Practice;2023-09-15

4. Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios;Journal of Clinical Medicine;2023-09-13

5. Weighing in on Direct Oral Anticoagulant Dosing in Patients With Obesity;The American Journal of Cardiology;2023-09